The Proto Oncogene Tyrosine Protein Kinase Receptor Ret pipeline drugs market research report outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Receptor Ret targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Proto Oncogene Tyrosine Protein Kinase Receptor Ret pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Non Malignant Disorders, Undisclosed, and Gastrointestinal which include the indications Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Benign Tumor, Plexiform Neurofibroma, Unspecified, Irritable Bowel Syndrome, and Diarrhea. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Receptor Ret targeted therapeutics development with respective active and dormant or discontinued products.
The Proto Oncogene Tyrosine Protein Kinase Receptor Ret pipeline targets constitutes close to 50 molecules. Out of which, approximately 42 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 10, 10, 7, 1, 7, and 6 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 3 molecule.
Proto Oncogene Tyrosine Protein Kinase Receptor Ret overview
Proto oncogene tyrosine protein kinase receptor Ret is a receptor tyrosine kinase (RTK) that plays a critical role in various cellular processes, including cell proliferation, differentiation, migration, and survival. It is a member of the RET family of RTKs. RET is activated by binding to members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands, which includes GDNF, neurturin, and artemin.
For a complete picture of Proto Oncogene Tyrosine Protein Kinase Receptor Ret’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
